Efficacy and Mechanisms of Action of Lithium Augmentation in Refractory Major Depression
The DOI matches its Crossref record.
Abstract
Lithium augmentation refers to the addition of lithium to an antidepressant in the acute treatment phase of patients with depressive episodes who have failed to respond satisfactorily to treatment with antidepressant monotherapy. This article reviews the clinical evidence and hypotheses on the mode of action of lithium augmentation. For this purpose, studies were identified by searching Medline and by scanning the references of published reviews and standard textbooks. With regard to efficacy, 28 prospective studies (with a total of 838 depressed patients) were identified. The majority of randomized controlled trials has demonstrated substantial efficacy of lithium augmentation. A recent meta-analysis including only double-blind, placebo-controlled trials (N = 9) provided firm evidence that lithium augmentation has a statistically significant effect on response rate compared to placebo, and showed that lithium augmentation should be administered for at least 2 weeks to allow assessment of the patient's response. A recent double-blind, placebo-controlled trial revealed that responders to lithium augmentation should be maintained on the lithium-antidepressant combination for a minimum of 12 months. From animal studies there is robust evidence that lithium augmentation increases serotonin (5-HT) neurotransmission, possibly through a synergistic action of lithium and the antidepressant on brain 5-HT pathways. Neuroendocrine studies in humans on the effects of lithium augmentation on the HPA system showed an unexpected and marked increase in the ACTH and cortisol response in the combined dexamethasone/CRH test. These results are in contrast to the established decline of HPA system activity during treatment with antidepressants. In conclusion, lithium is the foremost and most well-documented augmentation strategy in refractory depression. In international treatment guidelines and algorithms, lithium augmentation is considered a first-line treatment strategy for patients with a major depressive episode who do not adequately respond to standard antidepressant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Benedetti, F., Riccaboni, R., Locatelli, C., Poletti, S., Dallaspezia, S., & Colombo, C. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08455 · Cited by 116
Carvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00846.x · Cited by 110
“Lithium has a net enhancing effect on serotonergic (5-HTergic) neurotransmission (43).”
BackgroundLithium in the treatment of major depressive disorder
Bschor, T. (2014) · Drugs · doi:10.1007/s40265-014-0220-x · Cited by 94
“Lithium augmentation involves the addition of lithium to an antidepressant that after a sufficient period of time has proven not to be effective [24].”
BackgroundSelf-citationSuicidal Behavior in Mood Disorders: Response to Pharmacological Treatment
Tondo, L., & Baldessarini, R. J. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0715-0 · Cited by 71
Saelens, J., Gramser, A., Watzal, V., Zarate, C. A., Lanzenberger, R., & Kraus, C. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-02044-5 · Cited by 51
Metadata
- Authors
- Bschor, T., & Bauer, M.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-08-01
- Volume
- 12
- Issue
- 23
- Pages
- 2985-2992
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1965120165
- Cited by
- 73
- References
- 0
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Mechanisms of Action of Lithium Augmentation in Refractory Major Depression. https://app.cochat.ai/papers/10.2174/138161206777947650
- The paper
- Bschor, T., & Bauer, M. (2006). Efficacy and Mechanisms of Action of Lithium Augmentation in Refractory Major Depression. Current Pharmaceutical Design. https://doi.org/10.2174/138161206777947650
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.